MACQUARIE UNIVERSITY CANCER BIOBANK

MQCB00067A REPORT

07 OCTOBER 2022

CLINICAL SUMMARY

Sex: Male
Age: 73
Pre-operative radiotherapy: Unknown



>75% Tumour Content

HISTOPATHOLOGY

Specimen type: Brain
Tumour site: Right Frontal
Tumour type: Glioblastoma
Tumour stage: Grade IV (WHO 2016), IDH1 Wildtype, ATRX retained, MGMT Promoter Methylated

NEXT GENERATION GENOME/TRANSCRIPTOME DATA

Provider: Australian Genome Research Facility - 150bp paired end
Data yield: Germline DNA: 321,779,554 paired end, 97.18 Gbp
Tumour DNA: 920,170,726 paired end, 277.89 Gbp
Tumour RNA: 50,095,075 paired end, 15.13 Gbp

Top pathogenic somatic mutations			
Gene	**Alteration**	**Allele Frequency**	**Function**
EGFR	c.664C>T, p.R222C	59%	Gain
TERT	c.-124C>T, promoter alteration	38%	Gain
RB1	c.13A>C, T5P	24%	Loss

FLOW CYTOMETRY TUMOUR DISSOCIATE ANALYSIS





Cell Type	(%) of subset
Viable cells	9.4
Viable>CD45+	27.0
Viable>CD45+>CD3+	8.7
Viable>SOX2+	73.0
Viable>SOX2+>GFAP+	49.7
Viable>SOX2+>Nestin+	92.5
Viable>SOX2+>CD44+	32.4
Viable>SOX2+>CD133+	38.9